The patch study.

WECALM / REPORT CL/144/1125/STU

Who and what were tested?

Product / batch

WECALM Lotion / CP-EZML-026-007-003

Participants

26 adults completed: 13 with normal skin and 13 with sensitive skin. Actual ages 18–51; 13 men and 13 women. The report describes the normal-skin group as men and the sensitive-skin group as women.

Sensitivity screening

Lactic-acid sting testing in the nasolabial area. This was screening; the WECALM patch was applied to the back.

Design

Single-centre, non-randomised, single-blind, controlled, single-application study.

Application

Approximately 0.04 g, neat, under complete occlusion on healthy back skin for 24 hours. Scored at 48 hours, with follow-up one week after application.

Controls

1% sodium lauryl sulphate and 0.9% isotonic saline.

Dates

Study: 11–20 December 2025. Report: 26 December 2025. Certificate: 7 January 2026.

Sponsor

Monocure Pharma. Conducted under a dermatologist principal investigator with ethics-committee approval.

Read the result completely.

Three participants had non-zero combined irritation scores: 3, 1 and 1. The average was 0.19/8. Therefore the classification does not mean that every participant had zero irritation. The report separately states that no study-related adverse events or intolerances were observed.

No statistical hypothesis testing was performed. This is a batch-specific primary-irritation study, not a customer survey, recommendation, allergy test or trial of eczema, psoriasis, itch relief or barrier repair.

What it means for your routine

The findings support the narrow statement that this batch was dermatologically patch tested and classified Non-Irritant under these conditions. Individual reactions remain possible. Follow the pack, check known sensitivities and stop if irritation develops.

Children, pregnant or breastfeeding participants, and people with relevant disease or pathology at the test site were not represented by these results. Formula or ingredient-source changes may require retesting.

Source record

Summary prepared from the supplied clinical study report CL/144/1125/STU (pages 6, 8–12 and 14) and its WECALM claims certificate. Original documents and laboratory branding are not reproduced here. This is a sponsor-prepared summary, not a peer-reviewed publication or laboratory endorsement of this website.